The SYMPHONY trial found reboxetine can significantly reduce cataplexy, excessive daytime sleepiness, cognitive impairment, depression, and anxiety for patients with narcolepsy.
ZURICH, SWITZERLAND / ACCESSWIRE / November 27, 2023 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP, NLSPW)) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery
NLS Pharmaceutics AG: NLS Pharmaceutics to Participate in the Oppenheimer Sleep Disorders Summit: Deep Dive into Narcolepsy and Idiopathic Hypersomnia finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.